Please login to the form below
lung cancer
This page shows the latest lung cancer news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
Pfizer’s Lorbrena has come out on top in a head-to-head trial against its older ALK inhibitor Xalkori in previously untreated non-small cell lung cancer (NSCLC) with this ... These results of the CROWN study support the use of Lorbrena as a highly
Latest news
-
AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
lung cancer,” said José Baselga, executive vice president of Oncology R&D at AZ. ... Approximately a quarter of global lung cancer cases are EGFR-mutated, although in Asia the rate can climb to over 40% of new cases.
-
Gilead agrees $21bn buyout of Immunomedics
Immunomedics is also testing Trodelvy’s potential in non-small cell lung cancer as well as other solid tumour types, as both a monotherapy and in combination with checkpoint inhibitors. ... Trodelvy is an approved, transformational medicine for a form
-
Merck signs separate agreements with Seattle Genetics for two cancer drugs
LIV-1, which is quickly emerging as a novel cancer target, is expressed in most metastatic breast cancers and has also been observed in several other cancer types, such as lung, ... Ladiratuzumab vedotin binds to LIV-1 on cancer cells, where it then
-
AZ scores FDA priority review for new Imfinzi fixed-dose regimen
This includes unresectable, stage three non-small cell lung cancer (NSCLC) after chemoradiation therapy and previously-treated advanced bladder cancer. ... The disappointing results in SCLC marred an otherwise dominant position in lung cancer for
-
Eli Lilly, Innovent showcase Tyvyt data in first-line NSCLC
Detailed phase 3 results presented at the virtual World Conference on Lung Cancer. ... NSCLC is the most common type of lung cancer, accounting for 85% of all new cases.
More from news
Approximately 107 fully matching, plus 824 partially matching documents found.
Latest Intelligence
-
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches
Despite rapid advances in the field of immuno-oncology that have transformed the cancer treatment landscape, many cancer patients are still left behind. ... the other is designed to engage with any tumour-specific antigen, for example DLL3 in small-cell
-
Addressing the payer-regulator evidence gap in early-stage cancer
As part of the Lung Ambition Alliance, a partnership with the International Association for the Study of Lung Cancer (IASLC), Guardant Health and the Global Lung Cancer Coalition (GLCC), AstraZeneca is ... working to validate relevant endpoints to
-
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
Selumetinib was given ‘breakthrough therapy’ status and rapidly green-lit by the FDA last month (April) following a promising National Cancer Institute (NCI) Cancer Therapy Evaluation Program sponsored phase 2 trial. ... targets of small cell lung
-
Staying ahead in the era of precision medicine
For example, Lung-MAP, a large-scale umbrella trial in non-small cell lung cancer, was one of the first to involve partnerships between several groups including the FDA, NCI, advocacy ... The challenges around precision medicine are illustrated perfectly
-
Putting commercial intelligence at the heart of strategy
However, MSD’s narrow patient screening approach eventually proved to be crucial in extending overall first-line survival in non-small-cell lung cancer patients.
More from intelligence
Approximately 1 fully matching, plus 58 partially matching documents found.
Latest appointments
-
Astellas bolsters oncology clinical development leadership
breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.
-
Iris Pauporté joins OSE Immunotherapeutics
Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research
-
Astellas promotes John Demaree
Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice
-
Merck appoints ex-Pfizer exec as global head of oncology
lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer.
-
Merck appoints new senior vice president
Radvanyi will focus on leading the discovery of oncology therapies that leverage the natural ability of the body's immune system to fight cancer, as well as identifying biomarkers with the ... indications including lung, cervical and breast cancer.
More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest from PMHub
-
July 2020: diversity and inclusion in clinical trials round-up
Black people are among those who typically suffer poorer health outcomes from lung cancer. ... Early next year, a Stand Up To Cancer Innovation Summit will launch the project, which will bring together lung cancer experts with researchers specializing in
-
Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. ... 2017 Jul 11; 318(2):197-198. Denis F, Basch E et al. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine
-
Early diagnosis underpins NHS cancer strategy
lung cancer, have shown the value of bringing these kinds of services closer to patients’ homes. ... For example, most lung cancer diagnoses are made at stage four.
-
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
Lenalidomide. Revlimid. Celgene. Thalidomide. Thalomid. Celgene. Melphalan. Multiple brands. -. Erlotinib. Tarceva. Genentech. Front-line treatment of EGFR mutation positive advanced non-small cell lung cancer. ... Non-small cell lung cancer treatments,
-
Artificial Intelligence in healthcare
trust the same digital system to recommend their treatment pathway for a potentially lethal cancer. ... Early experience with IBM Watson for Oncology (WFO) cognitive computing system for lung and colorectal cancer treatment.
More from PMHub
Approximately 3 fully matching, plus 14 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Moderna inks R&D agreements with Vertex and Chiesi
- Shionogi's Gram-negative antibiotic launches in the UK
- Eli Lilly reports first results for COVID-19 targeting antibody
- Live Webinar: Medical Modeling in Virtual Reality
- Live Webinar: Telemedicine & the Digitization of Medicine post COVID-19
- Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
- AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
PMHub
Spirit
We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
